SCHEMBL2883013

SCHEMBL2883013

Cc1ccc(F)cc1C1=CCN(Cc2ccccc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 2/20 0.55
CDK9 P50750 2/20 0.55
DRD2 P14416 7/20 0.52
HTR1A P08908 4/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
HTR2A P28223 2/20 0.52
HTT P42858 1/20 0.52
MAPK1 P28482 1/20 0.50
OPRM1 P35372 1/20 0.50
OPRK1 P41145 1/20 0.50
HTR6 P50406 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
ATM Q13315 1/20 0.46
DRD4 P21917 3/20 0.46
DRD3 P35462 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2883008 0.90 DRD2 (0.52) CCNT1CDK9DRD2HTR1AMEN1
SCHEMBL6179323 0.84 CCNT1 (0.67) CCNT1CDK9DRD2HTR1AMEN1
SCHEMBL2395487 0.84 DRD2 (0.59) DRD2HTR1AHTR2AHTTOPRM1
SCHEMBL11437532 0.81 DRD2 (0.55) DRD2HTR1AHTR2AHTTOPRM1
SCHEMBL2395917 0.80 MAPK1 (0.69) DRD2HTR1AMEN1KMT2AHTR2A
SCHEMBL6043002 0.79 DRD2 (0.59) DRD2HTR1AMEN1KMT2AHTR2A
SCHEMBL74825 0.78 CCNT1 (0.49) CCNT1CDK9DRD2HTR1AMEN1
SCHEMBL6075980 0.78 DRD2 (0.58) DRD2HTR1AMEN1KMT2AHTR2A
SCHEMBL6043125 0.78 MEN1 (0.58) DRD2HTR1AMEN1KMT2AHTR2A
SCHEMBL6710633 0.77 DRD2 (0.54) DRD2HTR1AHTR2AHTTOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7855294-B2 Cycloalkanopyridine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-12-21 US disclosed
US-20070191419-A1 Cycloalkanopyridine derivative MSD K.K. (JP) 2007-08-16 US disclosed
EP-1726590-A1 CYCLOALKANOPYRIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191419-A1 Cycloalkanopyridine derivative OPRL1, OPRK1, AVPR2 CCNT1 2960/4885CDK9 3036/4885DRD2 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.